Alternative pricing models for remdesivir and other potential treatments for COVID-19

Alternative pricing models for remdesivir and other potential treatments for COVID-19

Collection:
Health Policy and Services Research
Author(s):
Whittington, Melanie D., author
Campbell, Jonathan D., author
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 24, 2020
Language(s):
English
Format:
Text
Subject(s):
Antiviral Agents -- economics
Coronavirus Infections -- drug therapy
Drug Costs
Models, Economic
Pandemics
Pneumonia, Viral -- drug therapy
United States
Genre(s):
Technical Report
Abstract:
The objective of this updated analysis was to provide estimates for the pricing of remdesivir in the treatment of COVID-19 that would represent a "cost recovery" approach. In this updated analysis, we present two cost recovery pricing estimates: 1) a price per treatment course that covers the minimal costs of production of the treatment; and 2) a price per treatment course that covers the cost of production plus the projected short-term spending by the manufacturer for clinical research directly related to the use of remdesivir for COVID-19.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (18 pages))
Illustrations:
Illustrations
NLM Unique ID:
101769591 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101769591